 |
|
|
|
 |
A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients with Newly Diagnosed Glioblastoma
[Protocol 08-126]
- Full Title :
- A PHASE II STUDY OF BEVACIZUMAB, TEMOZOLOMIDE AND HYPOFRACTIONATED RADIOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED MALIGNANT GLIOMA
- Purpose :
The purpose of this study is to evaluate the safety and effectiveness of a new combination of treatments for newly diagnosed glioblastoma. The first treatment approach for glioblastoma is usually focused radiation given over six weeks in combination with a chemotherapy drug called temozolomide. In this study, the radiation will be given as six doses over a two-week period in combination with temozolomide and another drug, bevacizumab.
Bevacizumab is a drug that is approved for treating advanced colorectal, breast, and lung cancers, and some studies have shown that it has activity against glioblastoma. It works by inhibiting the formation of the blood vessels that tumors need to grow and spread.
Researchers hope that this new combination of treatments may attack both the tumor and the blood vessels feeding the tumor more effectively than standard therapy.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of glioblastoma or grade IV glioma that has not yet been treated with chemotherapy, radiation therapy, or biologic therapy.
- At least 4 weeks must have passed since prior major surgery and entry into the study.
- Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Antonio Omuro at 212-639-7523.
|
|
|
|
|
